Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
The trial investigates the use of YCANTH VP-102TO-208 for treating common warts in children and adults aged 2 years and older. This Phase 3 study is double-blind, randomized, and vehicle-controlled, aiming to evaluate the safety and effectiveness of YCANTH compared to a placebo vehicle. Common warts caused by the human papilloma virus HPV are the focus, excluding certain wart types and locations. Participants receive topical applications of either YCANTH or a placebo vehicle every 21 days for up to four treatments during a 75-day period. The treated warts are covered with occlusive tape overnight following the application. Treatment may be delayed if temporary local skin reactions occur, and participants must attend all scheduled treatment and follow-up visits regardless of wart clearance. In Japan, participants completing this study may join a long-term follow-up study for up to 54 weeks to monitor safety and efficacy. Participants undergo wart measurements, dermatologic exams, and evaluation of treatment responses during visits. Follow-up includes in-person visits and phone calls to assess clearance and monitor adverse events. Researchers measure the proportion of participants achieving complete wart clearance at Day 84 and monitor safety through adverse event reporting and skin reaction assessments. The total participant involvement spans screening, treatment, and follow-up periods totaling several months.
Actively Recruiting
Researchers are evaluating a new treatment approach using remibrutinib and omalizumab for adults with chronic spontaneous urticaria CSU who do not respond well to second-generation H1-antihistamines. This open-label, global, multi-center Phase 3 study aims to achieve fast and well-controlled disease within 24 weeks by assessing the safety and effectiveness of this treatment sequence. Participants will receive remibrutinib 25 mg twice daily for the first 12 weeks. After this period, those whose symptoms are well controlled UCT7 score 12 will continue remibrutinib, while participants with inadequate control UCT7 score <12 will add omalizumab 300 mg every 4 weeks. This treatment algorithm is designed to adapt based on participants response. Throughout the 24-week study, participants will complete daily urticaria symptom diaries and undergo regular assessments including urticaria activity scores and quality of life measurements. Researchers will monitor adverse events during and after treatment. The main outcome is the proportion of participants achieving low urticaria activity UAS7 6 by Week 24. Participants are expected to follow the study protocol closely and attend scheduled visits for evaluation and safety monitoring.